Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine

2 minute read

Boxes of Walvax Biotechnology's messenger RNA (mRNA) vaccine against the coronavirus disease (COVID-19) are seen displayed at a trade fair in Shanghai, China April 16, 2021. China Daily via REUTERS

Register now for FREE unlimited access to

MEXICO CITY, May 11 (Reuters) - Mexico plans to start a late-stage clinical trial this month for a COVID-19 vaccine candidate developed by China using similar technology to shots from Moderna (MRNA.O) and Pfizer (PFE.N), foreign minister Marcelo Ebrard said on Tuesday.

The phase III trial for the shot from China's Walvax Biotechnology (300142.SZ) using messenger RNA (mRNA) technology will start on May 30 and involve 6,000 volunteers, Ebrard said in a Tweet.

Walvax is working with the Academy of Military Science (AMS) and Suzhou Abogen Biosciences to jointly develop the shot known as ARCoV or ARCoVax, China's first mRNA vaccine to enter Phase III trials.

Register now for FREE unlimited access to

The shot could be stored at 2-8 degrees Celsius for six months, a much less stringent temperature requirement than shots from western rivals, an AMS researcher leading the vaccine project said in April during a presentation at a vaccine event.

Mexico has already received doses of other vaccines from China's Sinovac Biotech (SVA.O) and CanSino Biologics (6185.HK), and planned to order shots made by Sinopharm. read more

China is currently using five domestically developed vaccines in its inoculation drive, although none use mRNA technology, which contains instructions for human cells to produce proteins that mimic part of the coronavirus.

Register now for FREE unlimited access to
Reporting by Anthony Esposito; Editing by Andrew Heavens

Our Standards: The Thomson Reuters Trust Principles.